FierceBiotech 22 dic 2025 Boehringer spells out a $448M future for Rectify's ABC kidney disease program
FierceBiotech 22 dic 2025 Editor's corner: Fierce Medtech's top 10 stories of 2025 show how tech can treat
FierceBiotech 22 dic 2025 AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism
FierceBiotech 20 dic 2025 Looking ahead with BD’s Bilal Muhsin on what good AI can still do for healthcare
FierceBiotech 20 dic 2025 Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail
FierceBiotech 19 dic 2025 Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners
FierceBiotech 19 dic 2025 Galapagos ends turbulent year with mixed results for last remaining immunology asset